amodiaquine has been researched along with lumefantrine in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (31.67) | 29.6817 |
| 2010's | 34 (56.67) | 24.3611 |
| 2020's | 7 (11.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y | 1 |
| Cheong, SL; Ng, CH; Tibon, NS | 1 |
| Barihuta, T; Barutwanayo, M; Bosman, A; Ciza, A; Delacollette, C; Kamana, J; Karenzo, J; Mizero, L; Moyou-Somo, R; Nahimana, A; Ndaruhutse, J; Ndayiragije, A; Niyungeko, D; Niyungeko, E; Nyarushatsi, JP; Ringwald, P | 1 |
| Garner, P; Jones, K; Taylor-Robinson, D | 1 |
| Ali, AS; Björkman, A; Gil, JP; Mårtensson, A; Montgomery, SM; Msellem, MI; Olliaro, P; Sisowath, C; Strömberg, J | 1 |
| Balkan, S; Checchi, F; Guerin, PJ; Guthmann, JP; Pinoges, L; Rolland, E | 1 |
| Alaribe, A; Ejemot, R; Ekenjoku, J; Ezedinachi, E; Meremikwu, M; Nwachukwu, C; Ordu, D; Oyo-Ita, A | 1 |
| Balkan, S; Cohuet, S; Fortes, F; Francis, M; Guthmann, JP; Kiguli, J; Kyomuhendo, J; Mulemba, M; Noël, F; Rigutto, C; Saraiva, N | 1 |
| Al Attas, S; Balasegaram, M; Guthmann, JP; Kitz, C; Libama, F; van den Broek, I | 1 |
| Ahmed, J; Hallett, RL; Humphreys, GS; Merinopoulos, I; Mutabingwa, TK; Sutherland, CJ; Whitty, CJ | 1 |
| Dokomajilar, C; Dorsey, G; Joloba, M; Nsobya, SL; Rosenthal, PJ | 1 |
| Dieng, Y; Faye, B; Faye, O; Gaye, O; Ndiaye, D; Ndiaye, JL | 1 |
| Nyunt, MM; Plowe, CV | 1 |
| Abdulla, S; Kabanywanyi, AM; Mandike, R; Mugittu, K; Mwita, A; Sumari, D | 1 |
| Ademowo, OG; Falade, CO; Ladipo, SM; Ogundele, AO; Yusuf, BO | 1 |
| Adedeji, AA; Balogun, T; Bolaji, OM; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sowunmi, A | 1 |
| Adjuik, M; Amenga-Etego, S; Asante, KP; Chandramohan, D; Dosoo, DK; Greenwood, B; Gyapong, J; Owusu, R; Owusu-Agyei, S | 1 |
| Ashley, EA; Balkan, S; Bukirwa, H; Checchi, F; Dorsey, G; Guthmann, JP; Olliaro, P; Pinoges, L; Taylor, WR; Turyakira, E; Urruta, PP; van den Broek, I; van Herp, M; Zongo, I | 1 |
| Engl, M; Gluderer, D; Ogwang, M; Ploner, F; Ploner, M; Prugger, C; Wernsdorfer, G; Wernsdorfer, WH | 1 |
| Abiodun, O; Bell, A; Brun, R; Chollet, J; Irungu, BN; Kiboi, DM; Langat, B; Nganga, JK; Nyambati, VC; Nzila, A; Rukunga, GM; Wittlin, S | 1 |
| Adeothy, A; Amedome, H; Aubouy, A; Cot, M; Cottrell, G; Deloron, P; Doritchamou, J; Faucher, JF; Gourmel, B; Houzé, P; Kossou, H; Massougbodji, A | 1 |
| Annerberg, A; Aweeka, F; Clark, TD; Dorsey, G; Drysdale, T; German, P; Kalyango, JN; Kamya, MR; Lindegardh, N; McGee, B; Mwesigwa, J; Parikh, S; Rosenthal, PJ | 1 |
| Oguonu, T; Okafor, HU; Shu, EN | 1 |
| Dokomajilar, C; Greenhouse, B; Ouédraogo, JB; Rosenthal, PJ; Rouamba, N; Séré, YY; Somé, AF; Zongo, I | 1 |
| Clark, TD; Dorsey, G; Greenhouse, B; Kamya, MR; Maiteki-Sebuguzi, C; Njama-Meya, D; Nzarubara, B; Rosenthal, PJ; Staedke, SG | 1 |
| Amalvict, R; Baret, E; Briolant, S; Charras, S; Feraud, M; Henry, M; Huyghues des Etages, E; Pascual, A; Pradines, B; Rogier, C | 1 |
| Adjalley, SH; Eappen, AG; Eastman, RT; Ekland, EH; Fidock, DA; Hoffman, SL; Johnston, GL; Lee, MC; Li, T; Richman, A; Sim, BK | 1 |
| Córdoba, F; De la Hoz Restrepo, F; Porras Ramírez, A; Rico Mendoza, A; Rojas, DP | 1 |
| Genton, B; Manong, D; Mueller, I; Rarau, P; Reeder, JC; Rogerson, SJ; Salib, M; Senn, N; Siba, P | 1 |
| Adesina, O; Bassi, PU; Coulter, D; Isah, A; Jalo, I; Kalat, M; Nwoasu, SC; Nyong, EE; Osakwe, AI; Osungwu, F; Pal, S; Suku, C; Ugochukwu, C; Wallberg, M; Wammanda, RD | 1 |
| Arzika, I; Fandeur, T; Guillebaud, J; Issaka, M; Maazou, A; Salissou, A; Specht, S; Zamanka, H | 1 |
| Akala, HM; Andagalu, B; Bulimo, W; Cheruiyot, A; Eyase, FL; Ingasia, L; Johnson, JD; Juma, D; Kamau, E; Okudo, C; Omondi, A; Schnabel, D; Walsh, DS; Wanja, E; Waters, NC; Yeda, R | 1 |
| Aubouy, A; Dahlström, S; Deloron, P; Ezinmègnon, S; Faucher, JF; Houzé, P; Houzé, S; Kendjo, E; Le Bras, J; Maïga-Ascofaré, O; Massougbodji, A; Wakpo, A | 1 |
| Ademowo, OG; Dada-Adegbola, HO; Falade, CO; Nash, O; Oguike, MC; Ogunkunle, OO | 1 |
| Adam, I; Ademowo, G; Arze, C; Baliraine, FN; Berens-Riha, N; Björkman, A; Borrmann, S; Checchi, F; Dahal, P; Davis, TME; Desai, M; Dhorda, M; Djimdé, AA; Dorsey, G; El-Sayed, BB; Eshetu, T; Eyase, F; Falade, C; Faucher, JF; Fröberg, G; Gadalla, NB; Grivoyannis, A; Guérin, P; Hamour, S; Houzé, S; Johnson, J; Kamugisha, E; Kariuki, S; Kiechel, JR; Kironde, F; Kofoed, PE; LeBras, J; Malmberg, M; Mårtensson, A; Ménard, D; Moriera, C; Mwai, L; Ngasala, B; Nosten, F; Nsanzabana, C; Nsobya, SL; Nzila, A; Oguike, M; Ogutu, B; Otienoburu, SD; Ouédraogo, JB; Piola, P; Plowe, CV; Price, RN; Rombo, L; Rosenthal, PJ; Schramm, B; Sibley, CH; Somé, AF; Stepniewska, K; Sutherland, CJ; Thwing, J; Ursing, J; Venkatesan, M; Wong, RPM; Zeynudin, A; Zongo, I | 1 |
| Baret, E; Bercion, R; Camara, C; Diatta, B; Diémé, Y; Fall, B; Fall, KB; Fall, M; Mbaye, PS; Nakoulima, A; Pascual, A; Pradines, B; Wade, B; Wurtz, N | 1 |
| Adjei, GO; Alifrangis, M; Enweronu-Laryea, CC; Goka, BQ; Khalil, I; Kurtzhals, JA; Renner, L; Rodrigues, OP; Sulley, AM | 1 |
| Afizi, K; Fredrick, M; Kamya, MR; Lameyre, V; Lukwago, R; Talisuna, AO; Yeka, A | 1 |
| Bigira, V; Bloome, J; Byaruhanga, O; Conrad, MD; Cooper, RA; Dorsey, G; Greenhouse, B; Gut, J; Havlir, DV; Kakuru, A; Kamya, MR; Kapisi, J; Kozak, B; LeClair, N; Legac, J; Nakazibwe, C; Nsobya, SL; Okiring, J; Rosenthal, PJ; Tumwebaze, P; Walakira, A | 1 |
| Barnwell, JW; Goldman, I; Juma, E; Kariuki, S; Komino, F; Lucchi, NW; Okoth, SA; Onyona, P; Shi, YP; Udhayakumar, V; Wiegand, RE | 1 |
| Acheampong, PR; Antwi, GD; Bart Plange, C; Cairns, M; Chandramohan, D; Tagbor, H | 1 |
| Fairhurst, RM; Imwong, M; Kwiatkowski, DP; Lim, P; Miotto, O; Srimuang, K; Woodrow, CJ | 1 |
| Amalvict, R; Benoit, N; Briolant, S; Diatta, B; Diawara, S; Diémé, Y; Fall, B; Fall, M; Gendrot, M; Kounta, MB; Madamet, M; Nakoulima, A; Pradines, B; Wade, B; Wade, KA | 1 |
| Byaruhanga, O; Ceja, FG; Conrad, MD; Cooper, RA; Katairo, T; Nsobya, SL; Rasmussen, SA; Rosenthal, PJ; Tumwebaze, PK | 1 |
| Affara, M; Ahmad, A; Amambua-Ngwa, A; Ceesay, S; D'Alessandro, U; El-Fatouri, F; Janha, R; Joof, F; Kolly, O; Mbye, H; Nwakanma, D; Nyang, H; Okebe, J | 1 |
| Adewoye, EO; Agomo, C; Akano, K; Ambe, J; Ayede, AI; Ebenebe, J; Emechebe, G; Ezeigwe, N; Fatunmbi, B; Finomo, F; Folarin, OA; Gbotosho, GO; Happi, CT; Jiya, N; Mokuolu, O; Ntadom, G; Oguche, S; Oyibo, WA; Sowunmi, A; Useh, F; Wammanda, R; Wewe, OA | 1 |
| Dama, S; de Smet, M; Djimdé, A; Doumbo, OK; Etard, JF; Grandesso, F; Guindo, O; Laminou, IM; Makarimi, R; Ouwe Missi Oukem-Boyer, O; Rigal, J; Traore, A; Woi Messe, L | 1 |
| Alifrangis, M; Baraka, V; Francis, F; Lutumba, P; Mavoko, HM; Nabasumba, C; Van Geertruyden, JP | 1 |
| Ajeigbe, KO; Emikpe, BO; Olaleye, SB | 1 |
| Amara, A; Byakika-Kibwika, P; Chiong, J; Else, L; Gini, J; Kaboggoza, J; Khoo, SH; Lamorde, M; Tarning, J; Waitt, C; Walimbwa, SI; Winterberg, M | 1 |
| Hine, P; Pryce, J | 1 |
| Björkman, A; Garcia, S; Humphreys, GS; Otienoburu, SD; Srisutham, S; Suay, I; Thomas, NV | 1 |
| Abdel-Muhsin, AA; Abdelraheem, MH; Al Dhuhli, A; Al Hosni, A; Al Rubkhi, M; Al-Hamidhi, S; Babiker, HA; Bakhiet, AMA; Gadalla, A; Gismelseed, L; Kheir, A; Mukhtar, M; Naiem, A; Omer, S; Sultan, AA | 1 |
| Fungula, B; Inocencio da Luz, R; Kalabuanga, M; Lula Ntamba, Y; Lutumba, P; Muhindo Mavoko, H; Ntamabyaliro Nsengi, PM; Tona Lutete, G; Van Geertruyden, JP | 1 |
| Bonkian, LN; d'Alessandro, U; Kazienga, A; Lingani, M; Mens, PF; Ouédraogo, JB; Ravinetto, R; Schallig, HDFH; Sorgho, H; Tinto, H; Valéa, I; Yerbanga, I | 1 |
| Atusiimirwe, JK; Ayikobua, ET; Kalange, M; Kasolo, J; Kasozi, KI; Matama, K; Munanura, EI; Namulema, J; Nansunga, M; Okpanachi, AO; Semuyaba, I; Ssempijja, F; Zirintunda, G | 1 |
| Bihoun, B; Derra, K; Kazienga, A; Nakanabo-Diallo, S; Pagnoni, F; Rouamba, E; Rouamba, T; Samadoulougou-Kirakoya, F; Sondo, P; Sorgho, H; Tarnagda, Z; Tinto, H; Valea, I | 1 |
| Bah, S; Dabitao, D; Dama, S; Diakité, M; Diakité, SAS; Doumbia, S; Doumbouya, M; Guindo, MA; Keita, B; Konaté, DS; Sangaré, M; Sanogo, I; Traoré, K | 1 |
| Abuaku, B; Duah-Quashie, NO; Hagan, CO; Hodoameda, P; Koram, K; Matrevi, S; Quashie, NB | 1 |
| Anywar, DA; Auma, MA; Balikagala, B; Emoto, S; Fukuda, N; Hashimoto, M; Hirai, M; Horii, T; Ikeda, M; Kataoka, M; Katuro, OT; Kimura, E; Mita, T; Mori, T; Obwoya, PS; Odongo-Aginya, EI; Ogwang, M; Opio, W; Palacpac, NMQ; Sakurai-Yatsushiro, M; Sekihara, M; Tachibana, SI; Yamauchi, M; Yatsushiro, S | 1 |
3 review(s) available for amodiaquine and lumefantrine
| Article | Year |
|---|---|
Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
Topics: Animals; Antimalarials; Artemisinins; Drug Discovery; Drug Resistance; Humans; Malaria; Molecular Structure; Paclitaxel; Quinolines | 2020 |
Malaria: uncomplicated, caused by Plasmodium falciparum.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Dapsone; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Mefloquine; Proguanil; Pyrimethamine; Sesquiterpenes; Sulfadoxine | 2005 |
Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy, Combination; Humans; Liver; Lumefantrine; Malaria, Falciparum; Mefloquine; Naphthyridines; Randomized Controlled Trials as Topic | 2019 |
25 trial(s) available for amodiaquine and lumefantrine
| Article | Year |
|---|---|
Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Odds Ratio; Plasmodium falciparum; Sesquiterpenes; Tanzania | 2005 |
Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Nigeria; Plasmodium falciparum; Sesquiterpenes; Treatment Outcome | 2006 |
High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola.
Topics: Amodiaquine; Angola; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Sesquiterpenes; Treatment Outcome | 2006 |
Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; Democratic Republic of the Congo; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Plasmodium falciparum; Sesquiterpenes; Treatment Outcome | 2006 |
Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child, Preschool; Drug Resistance; Ethanolamines; Female; Fluorenes; Genetic Linkage; Genotype; Haplotypes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Plasmodium falciparum; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Tanzania; Treatment Outcome | 2007 |
Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Mutation; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Sesquiterpenes; Treatment Outcome; Uganda | 2007 |
Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal.
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Fluorenes; Follow-Up Studies; Humans; Infant; Lumefantrine; Malaria, Falciparum; Mefloquine; Middle Aged; Plasmodium falciparum; Pyrimethamine; Senegal; Sesquiterpenes; Sulfadoxine; Treatment Outcome | 2007 |
Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Child, Preschool; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Tanzania; Treatment Outcome | 2007 |
High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Nigeria; Plasmodium falciparum; Treatment Outcome | 2008 |
Activities of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine against sexual-stage parasites in falciparum malaria in children.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Male; Plasmodium falciparum; Pyrimethamine; Sulfalene; Survival Rate; Treatment Outcome | 2008 |
An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Dapsone; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria; Male; Polymerase Chain Reaction; Proguanil; Treatment Outcome | 2008 |
Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Benin; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Polymerase Chain Reaction; Pyrimethamine; Sulfadoxine | 2009 |
Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance.
Topics: Amodiaquine; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Follow-Up Studies; Gametogenesis; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Nigeria; Plasmodium falciparum; Polymerase Chain Reaction; Pyrimethamine; Sulfalene; Treatment Outcome | 2010 |
Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Incidence; Infant; Lumefantrine; Malaria; Male; Pyrimethamine; Sulfadoxine; Treatment Outcome; Uganda | 2010 |
Artesunate + amodiaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Colombian Pacific region: a noninferiority trial.
Topics: Adult; Amodiaquine; Antimalarials; Artemether; Artemisinins; Colombia; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Male; Treatment Outcome | 2012 |
Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Child, Preschool; Ethanolamines; Fluorenes; Humans; Infant; Kaplan-Meier Estimate; Lumefantrine; Malaria, Falciparum; Malaria, Vivax; Papua New Guinea; Prospective Studies; Treatment Outcome | 2013 |
Evaluation of the comparative efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (Artemoclo™) for the treatment of acute uncomplicated malaria in Nigerian children.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chlorpheniramine; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Genome, Protozoan; Humans; Infant; Lumefantrine; Malaria; Male; Nigeria; Polymerase Chain Reaction | 2014 |
A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria.
Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemether; Artemisinins; Blood Cell Count; Child; Child, Preschool; Drug Combinations; Ethanolamines; Fluorenes; Ghana; Hemoglobins; Humans; Lumefantrine; Malaria, Falciparum; Parasite Load; Survival Analysis | 2014 |
Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Child, Preschool; Data Collection; Drug Combinations; Ethanolamines; Female; Fever; Fluorenes; Hemoglobins; Humans; Infant; Insecticide-Treated Bednets; Lumefantrine; Malaria, Falciparum; Male; Parasite Load; Patient Compliance; Safety; Splenomegaly; Treatment Outcome; Uganda | 2014 |
Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Chemoprevention; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Ghana; Humans; Infant; Infant, Newborn; Lumefantrine; Malaria; Male; Pyrimethamine; Quinolines; Rain; Seasons; Sulfadoxine | 2016 |
Analysis of anti-malarial resistance markers in pfmdr1 and pfcrt across Southeast Asia in the Tracking Resistance to Artemisinin Collaboration.
Topics: Amodiaquine; Antimalarials; Artemisinins; Asia, Southeastern; DNA, Protozoan; Drug Resistance; Ethanolamines; Fluorenes; Gene Frequency; High-Throughput Nucleotide Sequencing; Humans; Lumefantrine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Mutation, Missense; Plasmodium falciparum; Polymerase Chain Reaction; Protozoan Proteins | 2016 |
Changing Antimalarial Drug Sensitivities in Uganda.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Aspartic Acid Endopeptidases; Child; Child, Preschool; Chloroquine; Drug Resistance; Ethanolamines; Female; Fluorenes; Gene Expression; Humans; Infant; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Male; Mefloquine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Mutation; Parasitic Sensitivity Tests; Plasmodium falciparum; Protozoan Proteins; Quinolines; Uganda; Young Adult | 2017 |
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Female; Humans; Infant; Kaplan-Meier Estimate; Lumefantrine; Malaria, Falciparum; Male; Niger; Parasite Load; Quinolines | 2018 |
Impact of treatment and re-treatment with artemether-lumefantrine and artesunate-amodiaquine on selection of Plasmodium falciparum multidrug resistance gene-1 polymorphisms in the Democratic Republic of Congo and Uganda.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Democratic Republic of the Congo; Drug Combinations; Ethanolamines; Fluorenes; Haplotypes; Humans; Lumefantrine; Malaria, Falciparum; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Single Nucleotide; Uganda | 2018 |
In vivo/ex vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Burkina Faso; Child; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Female; Humans; Infant; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Male; Mass Drug Administration; Plasmodium falciparum; Treatment Failure; Treatment Outcome | 2020 |
32 other study(ies) available for amodiaquine and lumefantrine
| Article | Year |
|---|---|
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance; Erythrocytes; Humans; Imidazoles; Liver; Malaria; Mice; Mice, Inbred BALB C; Molecular Structure; Piperazines; Plasmodium; Plasmodium berghei; Plasmodium falciparum; Plasmodium yoelii; Polymorphism, Single Nucleotide; Protozoan Proteins; Random Allocation; Small Molecule Libraries; Sporozoites | 2011 |
[Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi].
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Burundi; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Male; Rural Health; Sesquiterpenes; Treatment Failure; Urban Health; Vomiting | 2004 |
Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Cost-Benefit Analysis; Diagnostic Tests, Routine; Disease Outbreaks; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Health Care Costs; Humans; Lumefantrine; Malaria, Falciparum; Pregnancy; Pregnancy Complications, Infectious; Prevalence; Sensitivity and Specificity; Sesquiterpenes | 2006 |
Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Dapsone; Drug Design; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Global Health; Half-Life; Humans; Lumefantrine; Malaria; Mefloquine; Pregnancy; Pregnancy Complications, Infectious; Proguanil; Pyrimethamine; Quinine; Sesquiterpenes; Sulfadoxine | 2007 |
Different methodological approaches to the assessment of in vivo efficacy of three artemisinin-based combination antimalarial treatments for the treatment of uncomplicated falciparum malaria in African children.
Topics: Africa; Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; Databases as Topic; Drug Combinations; Ethanolamines; Fluorenes; Genotype; Humans; Infant; Lumefantrine; Malaria, Falciparum; Plasmodium falciparum; Polymerase Chain Reaction; Pyrimethamine; Sulfadoxine; Treatment Outcome | 2008 |
Malariological baseline survey and in vitro antimalarial drug resistance in Gulu district, Northern Uganda.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Cross-Sectional Studies; Developing Countries; Drug Resistance; Drug Therapy, Combination; Endemic Diseases; Ethanolamines; Evidence-Based Medicine; Female; Fluorenes; Health Surveys; Humans; Incidence; Infant; Lumefantrine; Malaria, Falciparum; Male; Parasitic Sensitivity Tests; Plasmodium falciparum; Refugees; Uganda; Young Adult | 2008 |
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Chloroquine; Disease Models, Animal; Drug Resistance; Ethanolamines; Female; Fluorenes; Lumefantrine; Malaria; Male; Mice; Parasitemia; Plasmodium berghei; Quinolines; Serial Passage | 2009 |
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
Topics: Amodiaquine; Antimalarials; Area Under Curve; Artemether; Artemisinins; Artesunate; Biotransformation; Body Weight; Child; Child, Preschool; Chromatography, Liquid; Drug Combinations; Ethanolamines; Female; Fluorenes; Half-Life; Humans; Longitudinal Studies; Lumefantrine; Male; Spectrophotometry, Ultraviolet; Uganda | 2010 |
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Burkina Faso; Drug Combinations; Drug Resistance, Bacterial; Ethanolamines; Fluorenes; Genotype; Humans; Infant; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins; Pyrimethamine; Quinolines; Randomized Controlled Trials as Topic; Recurrence; Sulfadoxine | 2010 |
In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs.
Topics: Amodiaquine; Antimalarials; Chloroquine; Ethanolamines; Fluorenes; Inhibitory Concentration 50; Lumefantrine; Mefloquine; Methylene Blue; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Quinine | 2011 |
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.
Topics: Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Blotting, Southern; Dose-Response Relationship, Drug; Ethanolamines; Fluorenes; Genetic Vectors; Germ Cells, Plant; Green Fluorescent Proteins; Luciferases; Lumefantrine; Malaria; Methylene Blue; Naphthyridines; Plasmodium falciparum; Quinolines; Sexual Development | 2011 |
Safety of Artemisinin-Based Combination Therapies in Nigeria: A Cohort Event Monitoring Study.
Topics: Adolescent; Adult; Amodiaquine; Anti-Infective Agents; Antimalarials; Artemisinins; Child; Child, Preschool; Cohort Studies; Ethanolamines; Female; Fluorenes; Humans; Infant; Infant, Newborn; Lumefantrine; Malaria; Male; Nigeria; Pregnancy; Prospective Studies; Young Adult | 2013 |
Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Naphthyridines; Niger; Parasitic Sensitivity Tests; Plasmodium falciparum; Quinolines | 2013 |
The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011.
Topics: Amodiaquine; Antimalarials; Chloroquine; DNA, Protozoan; Drug Resistance; Ethanolamines; Fluorenes; Haplotypes; Humans; Inhibitory Concentration 50; Kenya; Lumefantrine; Malaria, Falciparum; Mefloquine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins; Retrospective Studies | 2013 |
Plasmodium falciparum Polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin.
Topics: Amodiaquine; Antimalarials; Artemisinins; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Inhibitory Concentration 50; Lumefantrine; Male; Mefloquine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins; Pyrimethamine; Quinine; Sulfadoxine | 2014 |
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.
Topics: Amino Acid Substitution; Amodiaquine; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Chloroquine; Datasets as Topic; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Fluorenes; Genetic Markers; Genotype; Humans; Infant; Kaplan-Meier Estimate; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Risk Factors | 2014 |
Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin.
Topics: Adult; Amodiaquine; Antimalarials; Artemisinins; Biological Transport; Child; Chloroquine; Drug Resistance; Erythrocytes; Ethanolamines; Female; Fluorenes; Gene Expression; Haplotypes; Humans; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Male; Mefloquine; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Single Nucleotide; Quinine; Senegal | 2014 |
Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Chloroquine; Clinical Trials as Topic; Ethanolamines; Fluorenes; Humans; Infant; Lumefantrine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Quinine; Quinolines; Uganda | 2015 |
In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity.
Topics: Alleles; Amodiaquine; Animals; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Resistance; Epidemiological Monitoring; Ethanolamines; Fluorenes; Gene Dosage; Gene Expression; Genotype; Humans; Kenya; Lumefantrine; Malaria, Falciparum; Mefloquine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins | 2015 |
Association between Polymorphisms in the Pf
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Asparagine; ATP-Binding Cassette Transporters; Chloroquine; Doxycycline; Drug Resistance; Ethanolamines; Fluorenes; Gene Expression; Humans; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Mefloquine; Naphthyridines; Plasmodium falciparum; Polymorphism, Genetic; Protein Isoforms; Protozoan Proteins; Quinine; Quinolines; Repetitive Sequences, Amino Acid; Senegal | 2017 |
Sustained
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Fluorenes; Gambia; Humans; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Microsatellite Repeats; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins; Quinolines | 2017 |
Factors contributing to anaemia after uncomplicated falciparum malaria in under five year-old Nigerian children ten years following adoption of artemisinin-based combination therapies as first-line antimalarials.
Topics: Amodiaquine; Anemia; Antimalarials; Area Under Curve; Artemisinins; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Follow-Up Studies; Hematocrit; Humans; Infant; Kaplan-Meier Estimate; Logistic Models; Lumefantrine; Malaria, Falciparum; Male; Nigeria; Odds Ratio; Quinolines; ROC Curve; Treatment Outcome | 2017 |
Effects of artemisinin, with or without lumefantrine and amodiaquine on gastric ulcer healing in rat.
Topics: Amodiaquine; Animals; Artemisinins; C-Reactive Protein; Drug Therapy, Combination; Lumefantrine; Male; Neutrophil Infiltration; Rats; Rats, Wistar; Stomach Ulcer | 2018 |
Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine.
Topics: Adult; Amodiaquine; Antimalarials; Artemether; Artesunate; Breast Feeding; Cross-Over Studies; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; Humans; Lumefantrine; Male; Oxazines; Piperazines; Pyridones | 2019 |
An online mapping database of molecular markers of drug resistance in Plasmodium falciparum: the ACT Partner Drug Molecular Surveyor.
Topics: Amodiaquine; Antimalarials; Databases as Topic; DNA Copy Number Variations; Drug Resistance, Multiple; Lumefantrine; Mefloquine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Online Systems; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins | 2019 |
Evolution of Plasmodium falciparum drug resistance genes following artemisinin combination therapy in Sudan.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; DNA, Protozoan; Drug Resistance; Drug Therapy, Combination; Genetic Markers; Genotype; Humans; Lumefantrine; Malaria, Falciparum; Mutation; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Pyrimethamine; Sudan; Sulfadoxine | 2019 |
Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo.
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Child, Preschool; Clindamycin; Democratic Republic of the Congo; Drug Combinations; Female; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Plasmodium falciparum; Quinine | 2019 |
Antimalarial combination therapies increase gastric ulcers through an imbalance of basic antioxidative-oxidative enzymes in male Wistar rats.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artesunate; Drug Therapy, Combination; Gastric Mucosa; Glutathione; Indomethacin; Inflammation; Lumefantrine; Male; Malondialdehyde; Oxidative Stress; Rats; Rats, Wistar; Stomach Ulcer | 2020 |
Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Burkina Faso; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Lumefantrine; Malaria; Male; Pharmacovigilance; Pregnancy; Prospective Studies; Structure-Activity Relationship | 2020 |
Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Resistance; Endemic Diseases; Humans; Infant; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Mali; Mefloquine; Plasmodium falciparum; Quinine; Quinolines | 2020 |
Plasmodium falciparum genetic factors rather than host factors are likely to drive resistance to ACT in Ghana.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Drug Resistance; Ghana; Humans; Infant; Infant, Newborn; Lumefantrine; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Genetic; Quinolines | 2020 |
Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in Northern Uganda.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Lumefantrine; Mefloquine; Plasmodium falciparum; Quinine; Uganda | 2021 |